Venous thromboembolism (VTE) is a commonly diagnosed condition with significant morbidity and mortality [ 1 x [1] Kearon, C., Akl, E.A., Comerota, A.J., Prandoni, P., Bounameaux, H., Goldhaber, S.Z. et al. Antithrombotic therapy for VTE disease. Antithrombotic therapy and prevention of thrombosis (9th Edition): American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141: e419S–e494S ([Suppl.]) Crossref | PubMed | Scopus (1996) | Google Scholar See all References ] [1] . Current guidelines recommend patients with VTE to be initially treated with low-molecular-weight heparin (LMWH), unfractionated heparin or fondaparinux, followed by long-term anticoagulation, which is usually accomplished with vitamin K antagonists (VKA) [ 2 x [2] Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., and Albrechtsson, U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; : 515–518 Abstract | PubMed | Scopus (459) | Google Scholar See all References , 3 x [3] Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979; 301: 855–858 Crossref | PubMed | Scopus (475) | Google Scholar See all References ]. Recommendations for long-term therapy are based on randomized clinical trials [ 2 x [2] Lagerstedt, C.I., Olsson, C.G., Fagher, B.O., Oqvist, B.W., and Albrechtsson, U. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet. 1985; : 515–518 Abstract | PubMed | Scopus (459) | Google Scholar See all References , 3 x [3] Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D. et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med. 1979; 301: 855–858 Crossref | PubMed | Scopus (475) | Google Scholar See all References , 4 x [4] Levine, M.N., Hirsh, J., Gent, M., Turpie, A.G., Weitz, J., Ginsberg, J. et al. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost. 1995; 74: 606–611 PubMed | Google Scholar See all References , 5 x [5] Kearon, C., Ginsberg, J.S., Kovacs, M.J., Anderson, D.R., Wells, P., Julian, J.A. et al. Extended Low-Intensity Anticoagulation for Thromboembolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thrombo-embolism. N Engl J Med. 2003; 349: 631–639 Crossref | PubMed | Scopus (663) | Google Scholar See all References , 6 x [6] Ridker, P.M., Goldhaber, S.Z., Danielson, E., Rosenberg, Y., Eby, C.S., Deitcher, S.R. et al. Long-term, low-intensity warfarin therapy for prevention of recurrent venous thromboembolism. N Engl J Med. 2003; 348: 1425–1434 Crossref | PubMed | Scopus (721) | Google Scholar See all References , 7 x [7] Schulman, S., Rhedin, A.S., Lindmarker, P., Carlsson, A., Lärfars, G., Nicol, P. et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med. 1995; 332: 1661–1665 Crossref | PubMed | Scopus (883) | Google Scholar See all References , 8 x [8] Agnelli, G., Prandoni, P., Santamaria, M.G., Bagatella, P., Iorio, A., Bazzan, M. et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin optimal Duration Italian Trial Investigators. N Engl J Med. 2001; 345: 165–169 Crossref | PubMed | Scopus (520) | Google Scholar See all References , 9 x [9] Pinede, L., Ninet, J., Duhaut, P., Chabaud, S., Demolombe-Rague, S., Durieu, I. et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf vein thrombosis. Circulation. 2001; 103: 2453–2460 Crossref | PubMed | Scopus (352) | Google Scholar See all References , 10 x [10] Agnelli, G., Prandoni, P., Becattini, C., Silingardi, M., Taliani, M.R., Miccio, M. et al. Extended oral anticoagulant therapy after a first episode of pulmonary embolism. Ann Intern Med. 2003; 139: 19–25 Crossref | PubMed | Scopus (297) | Google Scholar See all References ] that assessed relevant outcomes like VTE recurrences and major bleeding rates, because most trials were underpowered to assess fatal VTE or fatal bleeding events. Furthermore, a number of patients are often excluded from randomized trials of anticoagulation because of co-morbid conditions, short life expectancy, pregnancy or contraindications to therapy, which means that treatment regimens based on the results from randomized clinical trials might not be generalisable to all patients with VTE.